22157.jpg
HIV Point of Care (POC) Tests Pipeline Landscape Report 2023: Comparative Analysis of Products at Different Stages of Development and Clinical Trials in Progress
March 13, 2024 11:31 ET | Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "HIV Point of Care (POC) Tests Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies" report has been...
MedMira Corp Logo no tagline.png
MedMira Strengthens and Expands Board
July 14, 2022 19:00 ET | MedMira Inc.
HALIFAX, Nova Scotia, July 14, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the appointment of Ms. Pascale Nini to the Board of Directors. In addition, Mr. Thomas...
Research Nester  Logo
Global HBsAg Testing Market to Grow at a Robust CAGR During 2022-2031; Market to Grow on Account of the Increasing Prevalence of Hepatitis B, and Rising Advancements in Biotechnology Sector
June 30, 2022 10:58 ET | Research Nester
New York, June 30, 2022 (GLOBE NEWSWIRE) -- As per the World Health Organization data, globally, as of 2019, 30.4 million persons (10.5% of the estimated hepatitis B population) were aware of their...
MedMira Corp Logo no tagline.png
MedMira Reports Third Quarter Results FY2022
June 29, 2022 22:00 ET | MedMira Inc.
HALIFAX, Nova Scotia, June 29, 2022 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended April 30, 2022. Profit and Loss Highlights ...
MedMira Corp Logo no tagline.png
MedMira Receives Patent for its Unique Quantitative Diagnostic System
June 06, 2022 07:48 ET | MedMira Inc.
HALIFAX, Nova Scotia, June 06, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the receipt of a U.S. patent (number 11,353,450) for their new innovative and quantitative...
MedMira Corp Logo no tagline.png
MedMira provides an update on the new In Vitro Diagnostic Medical Devices Regulation (IVDR) in the European Market
May 27, 2022 08:01 ET | MedMira Inc.
HALIFAX, Nova Scotia, May 27, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its regulatory progress in Europe and any market accepting the CE mark. MedMira...
MedMira Corp Logo no tagline.png
VYRA™ Product Line Update
May 20, 2022 08:52 ET | MedMira Inc.
HALIFAX, Nova Scotia, May 20, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on the Company’s regulatory work for Canada for its VYRA™ product line. On the...
MedMira Corp Logo no tagline.png
MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test
May 12, 2022 08:40 ET | MedMira Inc.
HALIFAX, Nova Scotia, May 12, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark...
MedMira Corp Logo no tagline.png
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada
March 09, 2022 08:17 ET | MedMira Inc.
HALIFAX, Nova Scotia, March 09, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trials underway in Canada....
MedMira Corp Logo no tagline.png
MedMira Receives CE Marking for its REVEALCOVID-19® PLUS Total Antibody Test
February 08, 2022 21:00 ET | MedMira Inc.
HALIFAX, Nova Scotia, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) has received the CE mark for its REVEALCOVID-19® PLUS Total Antibody Test. The test will be...